ACB Arrests DCO Handwara In Bribery Case

Kupwara: In a significant crackdown on corruption, Anti-Corruption Bureau (ACB) apprehended the Drug Control Officer (DCO) of Kupwara in the Bumhama area on Tuesday.

The arrest came in response to persistent complaints against the V.officer for soliciting and accepting bribes from a medical shop owner.

ACB officials revealed that a series of complaints prompted them to launch a meticulous operation to catch the corrupt officer. Despite evading previous traps, the DCO was caught red-handed during a carefully orchestrated operation on Tuesday.

The investigation unveiled that the officer had recently seized medicine from a medical store in the Villgam area. Instead of adhering to the prescribed procedure of taking the confiscated drugs to his office, he unlawfully left them at a medical store in Handwara.

The DCO identified as Ishtiyaq Ahmad allegedly demanded a bribe from a complainant for releasing the seized medicine, a deviation from the established norms. According to ACB officials, as mandated by regulations, the officer failed to provide the necessary receipt for the confiscated drugs.

The accused was subsequently taken to Handwara to identify the drugs left at the medical store. Reports indicate that the DCO had been extorting bribes from various medical shop owners, creating a hostile environment for them.

The news of the arrest quickly spread, earning praise from the public for the Anti-Corruption Bureau’s decisive action against employees engaging in corrupt practices.

Related Posts

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

Governments have moved for Price Transparency in Hospitals to help patients cope with bills

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction